Download PDF
Semin Thromb Hemost 2002; 28(4): 393-402
DOI: 10.1055/s-2002-34309
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Synthetic Pentasaccharide Fondaparinux: First in the Class of Antithrombotic Agents that Selectively Inhibit Coagulation Factor Xa

Maurice Petitou, Philippe Duchaussoy, Jean-Marc Herbert, Gérald Duc, Mohamed El Hajji, Jean-François Branellec, François Donat, José Necciari, Roger Cariou, Jean Bouthier, Eric Garrigou
  • Sanofi-Synthelabo, Toulouse, France
Further Information

Publication History

Publication Date:
23 September 2002 (online)

    Permissions and Reprints

ABSTRACT

Fondaparinux (Arixtra®), a synthetic pentasaccharide, is the first in a new class of antithrombotic agents that selectively inhibit coagulation factor Xa. In vitro experiments demonstrated that it is a selective inhibitor of factor Xa. In plasma, fondaparinux selectively binds to antithrombin, catalyzes factor Xa inhibition, and thereby inhibits thrombin generation. Its antithrombotic efficacy has been demonstrated in various animal models mimicking venous and arterial thrombosis. In humans, its pharmacokinetic profile is favorable, with a rapid onset of antithrombotic activity and an elimination half-life allowing a convenient once-daily dosing regimen. In several clinical trials, fondaparinux was more effective than the reference drug, enoxaparin, in preventing venous thromboembolism after hip fracture, major knee, and elective hip replacement surgeries. The overall reduction in the risk of venous thromboembolism ranged between 26.3 and 56.4%, depending on the trial. This superior efficacy was achieved without increasing the risk of clinically relevant bleeding. Fondaparinux also showed promising results in the treatment of patients with venous thromboembolism and acute coronary syndromes. Thus, it is now established that selective factor Xa inhibition is an efficient way to prevent venous thrombosis. The advent of fondaparinux offers an opportunity to improve substantially the management of venous thromboembolism.

KEYWORDS

Fondaparinux - pentasaccharide - antithrombin - thrombosis - antithrombotic - factor Xa

REFERENCES

  • 1 Casu B. Structure and biological activity of heparin.  Adv Carbohydr Chem Biochem . 1985;  43 51-134
    PubMedGoogle Scholar
  • 2 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest . 2001;  119 64S-94S
    CrossrefPubMedGoogle Scholar
  • 3 This point is best illustrated by the venue of symposia such as Differentiation of LMWHs: Applied and Clinical Considerations Fareed J, Haas S, Sasahara A, Chairpersons. January 29-30, 1999. St Petersburg, Florida. The objective of the meeting was ``To review the available data on the differentiation of LMWHs in clinical and applied sciences with leading experts in the field, and to develop a position paper for clinicians to better understand the feasibility of product substitution: its impact on clinical outcome.''
    Google Scholar
  • 4 Weitz J I, Hirsh J. New anticoagulant drugs.  Chest . 2001;  119 95S-107S
    CrossrefPubMedGoogle Scholar
  • 5 Eriksson B I. New therapeutic options in deep vein thrombosis prophylaxis.  Semin Hematol . 2000;  37 7-9
    PubMedGoogle Scholar
  • 6 Narayanan S. Multifunctional roles of thrombin.  Ann Clin Lab Sci . 1999;  29 275-280
    PubMedGoogle Scholar
  • 7 Wessler S, Yin E T. On the antithrombotic action of heparin.  Thromb Diath Haemorrh . 1974;  32 71-78
    PubMedGoogle Scholar
  • 8 Esmon C T, Owen W G, Jackson C M. The conversion of prothrombin to thrombin. II. Differentiation between thrombin- and factor Xa-catalyzed proteolyses.  J Biol Chem . 1974;  249 606-611
    PubMedGoogle Scholar
  • 9 Esmon C T, Jackson C M. The conversion of prothrombin to thrombin. III. The factor Xa-catalyzed activation of prothrombin.  J Biol Chem . 1974;  249 7782-7790
    PubMedGoogle Scholar
  • 10 Turpie A GG, Gallus A S, Hoek J A, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  N Engl J Med . 2001;  344 619-625
    CrossrefPubMedGoogle Scholar
  • 11 Lassen M R, Bauer K A, Eriksson B I, Turpie A GG. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in elective hip replacement surgery. A randomized double-blind comparison (in press).  Lancet.
    PubMedGoogle Scholar
  • 12 Turpie A GG, Bauer K A, Eriksson B I. A randomized double-blind comparison of fondaparinux with enoxaparin for the prevention of venous thromboembolism after elective hip replacement surgery (in press).  Lancet.
    PubMedGoogle Scholar
  • 13 Eriksson B I, Bauer K A, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med . 2001;  345 1298-1304
    CrossrefPubMedGoogle Scholar
  • 14 Bauer K A, Eriksson B I, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med . 2001;  345 1305-1310
    CrossrefPubMedGoogle Scholar
  • 15 The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ ORG31540) with pure anti-factor Xa activity. A phase II evaluation.  Circulation . 2000;  102 2726-2731
    PubMedGoogle Scholar
  • 16 Coussement P K, Bassand J P, Convens C. A synthetic factor Xa-inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction.  Eur Heart J . 2001;  22 1716-1724
    CrossrefPubMedGoogle Scholar
  • 17 Vuillemenot A, Schiele F, Meneveau N. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty.  Thromb Haemost . 1999;  81 214-220
    PubMedGoogle Scholar
  • 18 Choay J, Petitou M, Lormeau J-C. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.  Biochem Biophys Res Commun . 1983;  116 492-499
    PubMedGoogle Scholar
  • 19 van Boeckel A A C, Petitou M. The unique antithrombin binding domain of heparin: a lead to new synthetic antithrombotics.  Angew Chem Int Ed Engl . 1993;  32 1671-1690
    PubMedGoogle Scholar
  • 20 van Boeckel A A C, Beetz T, van Aelst F S. Synthesis of a potent antithrombin activating pentasaccharide: a new heparin-like fragment containing two 3-O-sulphated glucosamines.  Tetrahedron Lett . 1988;  29 803-806
    CrossrefPubMedGoogle Scholar
  • 21 Petitou M, Jaurand G, Derrien M, Duchaussoy P, Choay J. A, highly potent, heparin-like pentasaccharide fragment containing a glucose residue instead of a glucosamine. Bioorg Med Chem Lett .  1991;  2 95-98
    PubMedGoogle Scholar
  • 22 Westerduin P, van Boeckel A A C, Basten A. Feasible synthesis and biological properties of six ``non-glycosamino'' glycan analogues of the antithrombin III binding heparin pentasaccharide.  Bioorg Med Chem . 1994;  2 1267-1280
    PubMedGoogle Scholar
  • 23 Herbert J M, Hérault J P, Bernat A. Biochemical and pharmacological properties of SanOrg 34006, a potent and long-acting synthetic pentasaccharide.  Blood . 1998;  91 4197-4205
    PubMedGoogle Scholar
  • 24 Petitou M, Duchaussoy P, Lederman I. Synthesis of heparin fragments: a alpha-methyl pentaoside with high affinity for antithrombin III.  Carbohydr Res . 1987;  167 67-75
    CrossrefPubMedGoogle Scholar
  • 25 Jaurand G, Basten J, Lederman I, van Boeckel A A C, Petitou M. Biologically active heparin-like fragments with a ``non-glycosamino''glycan structure. Part 1: A pentasaccharide containing a 3-O-methyl iduronic acid unit.  Bioorg Med Chem Lett . 1992;  2 897-900
    CrossrefPubMedGoogle Scholar
  • 26 Basten J, Jaurand G, Olde-Hanter B, Petitou M, van Boeckel A A C. Biologically active heparin-like fragments with a ``non-glycosamino''glycan structure. Part 2: A tetra-O-methylated pentasaccharide with high affinity for antithrombin III.  Bioorg Med Chem Lett . 1992;  2 901-904
    CrossrefPubMedGoogle Scholar
  • 27 Basten J, Jaurand G, Olde-Hanter B. Biologically active heparin-like fragments with a ``non-glycosamino''glycan structure. Part 3: O-alkylated-O-sulphated pentasaccharides.  Bioorg Med Chem Lett . 1992;  2 905-910
    CrossrefPubMedGoogle Scholar
  • 28 Petitou M, Duchaussoy P, Lederman I, Choay J, Sinay P. Binding of heparin to antithrombin III: a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-d-glucose residue.  Carbohydr Res . 1988;  179 163-172
    CrossrefPubMedGoogle Scholar
  • 29 Petitou M, Lormeau J C, Choay J. Interaction of heparin and antithrombin III. The role of O-sulfate groups.  Eur J Biochem . 1988;  176 637-640
    CrossrefPubMedGoogle Scholar
  • 30 Jin J, Abrahams J P, Skinner R. The anticoagulant activation of antithrombin by heparin.  Proc Natl Acad Sci USA . 1997;  94 14683-14688
    CrossrefPubMedGoogle Scholar
  • 31 Belzar K J, Dafforn T R, Petitou M, Carrell R W, Huntington J A. The effect of a reducing-end extension on pentasaccharide binding to antithrombin.  J Biol Chem . 2000;  275 8733-6741
    CrossrefPubMedGoogle Scholar
  • 32 Herbert J M, Petitou M, Lormeau J C. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent.  Cardiovasc Drug Rev . 1997;  15 1-26
    PubMedGoogle Scholar
  • 33 Walenga J M, Peske W P, Bara L, Samama M M, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide.  Thromb Res . 1997;  86 1-36
    CrossrefPubMedGoogle Scholar
  • 34 Olson S T, Björk I, Sheffer R. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.  J Biol Chem . 1992;  267 12528-12538
    PubMedGoogle Scholar
  • 35 Lormeau J C, Herault J P, Herbert JM Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site of antithrombin. Thromb Haemost .  1996;  76 5-8
    PubMedGoogle Scholar
  • 36 Hérault J P, Gaich C, Bono F. Structural studies on synthetic oligosaccharides in relation to factor IXa inhibition (submitted for publication). 
    PubMedGoogle Scholar
  • 37 Lormeau J C, Herault J P. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic AT-III-binding pentasaccharide.  Thromb Haemost . 1993;  69 152-156
    PubMedGoogle Scholar
  • 38 Beguin S, Choay J, Hemker H C. The action of a synthetic pentasaccharide on thrombin generation in whole plasma.  Thromb Haemost . 1989;  61 397-401
    PubMedGoogle Scholar
  • 39 Walenga J M, Petitou M, Lormeau J C. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.  Thromb Res . 1987;  46 187-198
    CrossrefPubMedGoogle Scholar
  • 40 Amar J, Caranobe C, Sié P, Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit.  Br J Haematol . 1990;  76 94-100
    PubMedGoogle Scholar
  • 41 Carrié D, Caranobe C, Saivin S. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.  Blood . 1994;  84 2571-2577
    PubMedGoogle Scholar
  • 42 Vogel G MT, van Amsterdam G M R, Kop W J, Meuleman D G. Pentasaccharide and Orgaran® arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.  Thromb Haemost . 1993;  69 29-34
    PubMedGoogle Scholar
  • 43 Cadroy Y, Hanson S R, Harker L A. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.  Thromb Haemost . 1993;  70 631-635
    PubMedGoogle Scholar
  • 44 Hobbelen P MJ, Van Dinther G T, Vogel G MT. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.  Thromb Haemost . 1990;  63 265-270
    PubMedGoogle Scholar
  • 45 Walenga J, Petitou M, Samama M, Choay J, Fareed J. Importance of a 3-O-sulfate group in heparin pentasaccharide for antithrombotic activity.  Thromb Res . 1988;  52 553-563
    CrossrefPubMedGoogle Scholar
  • 46 Donat F, Duret J P, Santoni R. The pharmacokinetics of fondaparinux sodium in healthy volunteers.  Clin Pharmacokinet . 2002;  41(Suppl 2) 1-9
    PubMedGoogle Scholar
  • 47 Lieu C, Shi J, Donat F. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.  Clin Pharmacokinet . 2002;  41(Suppl 2) 19-26
    PubMedGoogle Scholar
  • 48 Faaij R A, Burggraaf J, Cohen A M. Lack of pharmacokinetic and pharmacodynamic interaction between the first synthetic factor Xa inhibitor and warfarin in human volunteers [abstract]. 42nd Annual Meeting of the American Society of Hematology; December 1-5, 2000; San Francisco
    Google Scholar
  • 49 Santoni A, Duvauchelle T. Safety and pharmacokinetics of co-administration of the first synthetic factor Xa inhibitor and aspirin in human volunteers [abstract]. 42nd Annual Meeting of the American Society of Hematology; December 1-5, 2000; San Francisco
    Google Scholar
  • 50 Mant T, Fournié P, Ollier C, Donat F, Necciari J. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers.  Clin Pharmacokinet . 2002;  41(Suppl 2) 43-49
    PubMedGoogle Scholar
  • 51 Lagrange F, Vergnes C, Brun J L. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra®) in the dually-perfused human cotyledon in vitro.  Thromb Haemost . 2002;  87 831-835
    PubMedGoogle Scholar
  • 52 Geerts W H, Heit J A, Clagett G P. Sixth ACCP Consensus Conference on antithrombotic therapy. Prevention of venous thromboembolism.  Chest . 2001;  119(Suppl) 132S-175S
    CrossrefPubMedGoogle Scholar
  • 53 Nicolaides A N. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.  Int Angiol . 2001;  20 1-37
    PubMedGoogle Scholar
  • 54 Davidson B L. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis?.  Haemostasis . 1998;  28(Suppl 3) 113-119
    CrossrefPubMedGoogle Scholar
  • 55 Kearon C, Julian J A, Math M, Newman T E, Ginsberg J S, for the McMaster Diagnostic Imaging Practice Guidelines Initiative. Noninvasive diagnosis of deep venous thrombosis Ann Intern Med .  1998;  128 663-677
    Google Scholar
  • 56 Levieux A, Rivera V, Levieux D. Immunochemical control of the species origin of porcine crude heparin and detection of ovine and caprine materials.  J Pharm Biomed Anal . 2002;  27 305-313
    CrossrefPubMedGoogle Scholar
  • 57 Jaques L B. Heparins-anionic polyelectrolyte drugs.  Pharmacol Rev . 1979;  31 99-167
    PubMedGoogle Scholar
  • 58 Conrad H E. Heparin-Binding Proteins.  San Diego, CA: Academic Press; 1998
    Google Scholar
  • 59 Capila I, Linhardt R J. Heparin-protein interactions.  Angew Chem Int Ed Engl . 2002;  41 390-412
    PubMedGoogle Scholar
  • 60 Gray E, Cesmeli S, Lormeau J-C, Davies A B, Lane D A. Low affinity heparin is an antithrombotic agent.  Thromb Haemost . 1994;  71 203-207
    PubMedGoogle Scholar
  • 61 Barzu T, Mohlo P, Tobelem G. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.  Nouv Rev Fr Hematol . 1984;  26 243-247
    PubMedGoogle Scholar
  • 62 Barzu T, Mohlo P, Tobelem G, Petitou M, Caen J P. Binding and endocytosis of heparin by human endothelial cells in culture.  Biochim Biophys Acta . 1985;  845 196-203
    PubMedGoogle Scholar
  • 63 Zammit A, Pepper D S, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma.  Thromb Haemost . 1993;  70 951-958
    PubMedGoogle Scholar
  • 64 Baruch D, Ajzenberg N, Denis C. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III.  Thromb Haemost . 1994;  71 141-146
    PubMedGoogle Scholar
  • 65 Boneu B, Caranobe C, Cadroy Y. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit.  Semin Thromb Hemost . 1998;  14 18-27
    PubMedGoogle Scholar
  • 66 Paolucci F, Clavies M C, Donat F, Necciari J. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins (in press). 
    PubMedGoogle Scholar
  • 67 Hoffmann P, Bernat A, Dumas A. The synthetic pentasaccharide SR90107A/ORG 31540 does not release lipase activity into the plasma.  Thromb Res . 1997;  326 325-332
    PubMedGoogle Scholar
  • 68 Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin.  Glycobiology . 1993;  3 271-277
    PubMedGoogle Scholar
  • 69 Elalamy I, Lecrubier C, Potevin F. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia.  Thromb Haemost . 1995;  74 1384-1385
    PubMedGoogle Scholar
  • 70 Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.  Thromb Haemost . 1995;  74 886-892
    PubMedGoogle Scholar
  • 71 Björk I, Olson S T, Shore J D. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Lane DA, Lindahl U, eds. Heparin London: Edward Arnold 1989: 229-255
    Google Scholar
  • 72 Lormeau J C, Hérault J P. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa.  Thromb Haemost . 1995;  74 1474-1477
    PubMedGoogle Scholar
  • 73 Ansell J, Hirsh J, Dalen J. Managing oral anticoagulant therapy.  Chest . 2001;  119 22S-38S
    CrossrefPubMedGoogle Scholar
  • 74 Petitou M, van Boeckel A A C. Heparin: from the original ``soup'' to well-designed heparin mimetics.  Pure Appl Chem . 1997;  67 1839-1846
    PubMedGoogle Scholar